Scott Long

Array ( [id] => 16563280 [patent_doc_number] => 10888627 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-01-12 [patent_title] => Nucleic acid products and methods of administration thereof [patent_app_type] => utility [patent_app_number] => 16/441563 [patent_app_country] => US [patent_app_date] => 2019-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 41 [patent_figures_cnt] => 63 [patent_no_of_words] => 121772 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16441563 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14960839 [patent_doc_number] => 20190307897 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-10 [patent_title] => NUCLEIC ACID PRODUCTS AND METHODS OF ADMINISTRATION THEREOF [patent_app_type] => utility [patent_app_number] => 16/441622 [patent_app_country] => US [patent_app_date] => 2019-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 121720 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -129 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16441622 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16703120 [patent_doc_number] => 10953033 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-23 [patent_title] => Compositions comprising circular polyribonucleotides and uses thereof [patent_app_type] => utility [patent_app_number] => 16/438073 [patent_app_country] => US [patent_app_date] => 2019-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 61 [patent_figures_cnt] => 64 [patent_no_of_words] => 53890 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 93 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16438073 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16153941 [patent_doc_number] => 20200215203 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-09 [patent_title] => RPGR GENE THERAPY FOR RETINITIS PIGMENTOSA [patent_app_type] => utility [patent_app_number] => 16/436521 [patent_app_country] => US [patent_app_date] => 2019-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9803 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16436521 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15469027 [patent_doc_number] => 10550378 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-02-04 [patent_title] => Composition comprising a gene vector that selectively depletes P16 positive senescent cells [patent_app_type] => utility [patent_app_number] => 16/436265 [patent_app_country] => US [patent_app_date] => 2019-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 9595 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16436265 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14864905 [patent_doc_number] => 20190282694 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-19 [patent_title] => IMMUNOPROTECTIVE PRIMARY MESENCHYMAL STEM CELLS AND METHODS [patent_app_type] => utility [patent_app_number] => 16/426911 [patent_app_country] => US [patent_app_date] => 2019-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12687 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16426911 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15206261 [patent_doc_number] => 20190365817 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-05 [patent_title] => POINT-OF-CARE AND/OR PORTABLE PLATFORM FOR GENE THERAPY [patent_app_type] => utility [patent_app_number] => 16/422876 [patent_app_country] => US [patent_app_date] => 2019-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44562 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16422876 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17799048 [patent_doc_number] => 11413315 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-16 [patent_title] => Neural stem cell-mediated cancer treatment [patent_app_type] => utility [patent_app_number] => 16/398108 [patent_app_country] => US [patent_app_date] => 2019-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 80 [patent_no_of_words] => 19898 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16398108 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14712329 [patent_doc_number] => 20190247228 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-15 [patent_title] => Ophthalmic Drug Delivery Method [patent_app_type] => utility [patent_app_number] => 16/398174 [patent_app_country] => US [patent_app_date] => 2019-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15142 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 149 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16398174 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16572166 [patent_doc_number] => 10894077 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-01-19 [patent_title] => Synthetic methylmalonyl-CoA mutase transgene for the treatment of MUT class methylmalonic acidemia (MMA) [patent_app_type] => utility [patent_app_number] => 16/390917 [patent_app_country] => US [patent_app_date] => 2019-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 11 [patent_no_of_words] => 9068 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16390917 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17602876 [patent_doc_number] => 11331345 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-05-17 [patent_title] => PD-1 CAR NK-92 cell and preparation method and use thereof [patent_app_type] => utility [patent_app_number] => 16/389954 [patent_app_country] => US [patent_app_date] => 2019-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 4433 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16389954 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16304143 [patent_doc_number] => 10772914 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2020-09-15 [patent_title] => EBV-specific immune cells [patent_app_type] => utility [patent_app_number] => 16/388776 [patent_app_country] => US [patent_app_date] => 2019-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 19 [patent_no_of_words] => 16960 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 160 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16388776 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15205923 [patent_doc_number] => 20190365648 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-05 [patent_title] => SYNTHETIC NANOSTRUCTURES INCLUDING NUCLEIC ACIDS AND/OR OTHER ENTITIES [patent_app_type] => utility [patent_app_number] => 16/384749 [patent_app_country] => US [patent_app_date] => 2019-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29036 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16384749 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14621763 [patent_doc_number] => 20190224249 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-25 [patent_title] => TREATMENT OF INTERVERTEBRAL DISC DEGENERATION [patent_app_type] => utility [patent_app_number] => 16/370456 [patent_app_country] => US [patent_app_date] => 2019-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10129 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16370456 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16244844 [patent_doc_number] => 10744172 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-08-18 [patent_title] => Tropism modified cancer terminator virus (Ad.5/3 CTV;Ad.5/3-CTV-M7) [patent_app_type] => utility [patent_app_number] => 16/369886 [patent_app_country] => US [patent_app_date] => 2019-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 46 [patent_figures_cnt] => 85 [patent_no_of_words] => 31386 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16369886 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16168205 [patent_doc_number] => 10709745 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-07-14 [patent_title] => Tropic cell based virotherapy for the treatment of cancer [patent_app_type] => utility [patent_app_number] => 16/361100 [patent_app_country] => US [patent_app_date] => 2019-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 67 [patent_figures_cnt] => 130 [patent_no_of_words] => 50450 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16361100 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17968443 [patent_doc_number] => 11485959 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-01 [patent_title] => Hyperactive piggybac transposases [patent_app_type] => utility [patent_app_number] => 16/358609 [patent_app_country] => US [patent_app_date] => 2019-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 12 [patent_no_of_words] => 18124 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16358609 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16414745 [patent_doc_number] => 10822622 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-11-03 [patent_title] => Methods for treating cells containing fusion genes [patent_app_type] => utility [patent_app_number] => 16/356587 [patent_app_country] => US [patent_app_date] => 2019-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 69 [patent_figures_cnt] => 76 [patent_no_of_words] => 33179 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 130 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16356587 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14868593 [patent_doc_number] => 20190284538 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-19 [patent_title] => RECOMBINANT ONCOLYTIC VIRUS, SYNTHETIC DNA SEQUENCE, AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 16/352806 [patent_app_country] => US [patent_app_date] => 2019-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5604 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16352806 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14924449 [patent_doc_number] => 20190297862 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-03 [patent_title] => Genetically Modified Mice and Engraftment [patent_app_type] => utility [patent_app_number] => 16/352674 [patent_app_country] => US [patent_app_date] => 2019-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20189 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16352674 [rel_patent_id] =>[rel_patent_doc_number] =>)